The pandemic has made unprecedented efforts worldwide to find safe and effective treatment, either by developing new drugs against the novel coronavirus or by repurposing existing drugs.
But very few of the drugs tested and administered to date have proven effective. This is borne out by a large WHO-backed study published on Friday.
The steroid dexamethasome is the only treatment that has been shown to reduce coronavirus mortality. It has shown promise in early studies in hospitalized patients in need of oxygen.
It has been recommended as a COVID-19 treatment by both the World Health Organization (WHO) and the European Medicines Agency.
But it remains something of a last resort drug – early evidence suggests it is only effective in the most serious cases.
Recent research has shown that other steroids may also play a role in reducing mortality in patients in need of hospital care.
Remdesivir, an antiviral agent originally developed to treat Ebola, reduced hospital stays for coronavirus patients from an average of 15 to 11 days, according to a study published in May New England Journal of Medicine.
However, a WHO form on Friday showed that the drug appeared to have “little or no effect” on coronavirus mortality or length of hospital stay in more than 11,000 hospital patients in 30 countries.
The data is yet to be reviewed in a scientific journal and appears to contradict previous US studies.
Hydroxychloroquine is perhaps the most controversial drug emerging from the pandemic. It is a malaria drug that is touted as a miracle cure by its proponents.
Critics warn, however, that the treatment of coronavirus patients with hydroxychloroquine is even worse than a placebo due to possible serious side effects.
While high-profile figures like US President Donald Trump seem convinced, science says otherwise.
In June, the UK-led recovery testing team said that hydroxychloroquine is doing nothing to reduce coronavirus mortality, which was confirmed by WHO study results on Friday.
This HIV virus, used against HIV, the virus that causes AIDS, has been shown to be ineffective in treating COVID-19 in hospitals.
When the body fends off viruses like SARS-CoV-2, it develops antibodies – proteins that are programmed to target specific pathogens.
These antibodies can be synthesized in a laboratory and theoretically administered to patients suffering from COVID-19 to boost their own natural immune response.
Trump received this still experimental treatment when he was hospitalized with the virus.
However, the WHO said again on Friday that the technology developed by the US biotech company Regeneron would have little or no benefit in hospitalized patients with coronavirus.
Plasma taken from the blood of recovered patients showed some early prospects when given intravenously to people suffering from COVID-19.
It has already been shown to speed recovery from Ebola and SARS, which are caused by the same family of pathogens as the novel coronavirus.
Recovery has an ongoing clinical trial on plasma treatment.
The UK-run survey is also currently evaluating the effectiveness of tocilizumab, an immunosuppressant drug that scientists hope can prevent excessive and potentially fatal inflammation in severe cases.
A number of studies are looking into the reuse of different drugs to treat other diseases.
Remdesivir has “little or no effect” on Covid-19 mortality: WHO study
© 2020 AFP
Quote: Coronavirus Treatments: Some Advances, Not a Panacea (2020, October 16), accessed October 17, 2020 from https://medicalxpress.com/news/2020-10-coronavirus-treatments-panacea.html
This document is subject to copyright. Except for fair trade for the purpose of private study or research, no part may be reproduced without written permission. The content is provided for informational purposes only.
These were the details of the news Coronavirus treatments: some advances, not a panacea for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at de24.news and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.